1. Home
  2. ADPT vs KRO Comparison

ADPT vs KRO Comparison

Compare ADPT & KRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • KRO
  • Stock Information
  • Founded
  • ADPT 2009
  • KRO 1916
  • Country
  • ADPT United States
  • KRO United States
  • Employees
  • ADPT N/A
  • KRO N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • KRO Major Chemicals
  • Sector
  • ADPT Health Care
  • KRO Industrials
  • Exchange
  • ADPT Nasdaq
  • KRO Nasdaq
  • Market Cap
  • ADPT 1.2B
  • KRO 1.1B
  • IPO Year
  • ADPT 2019
  • KRO N/A
  • Fundamental
  • Price
  • ADPT $8.27
  • KRO $8.75
  • Analyst Decision
  • ADPT Buy
  • KRO Hold
  • Analyst Count
  • ADPT 5
  • KRO 3
  • Target Price
  • ADPT $9.10
  • KRO $12.00
  • AVG Volume (30 Days)
  • ADPT 1.4M
  • KRO 125.4K
  • Earning Date
  • ADPT 02-11-2025
  • KRO 03-05-2025
  • Dividend Yield
  • ADPT N/A
  • KRO 2.29%
  • EPS Growth
  • ADPT N/A
  • KRO N/A
  • EPS
  • ADPT N/A
  • KRO 0.82
  • Revenue
  • ADPT $178,957,000.00
  • KRO $1,864,100,000.00
  • Revenue This Year
  • ADPT $20.07
  • KRO $25.77
  • Revenue Next Year
  • ADPT $25.27
  • KRO $6.54
  • P/E Ratio
  • ADPT N/A
  • KRO $10.67
  • Revenue Growth
  • ADPT 5.10
  • KRO 15.87
  • 52 Week Low
  • ADPT $2.28
  • KRO $8.51
  • 52 Week High
  • ADPT $8.95
  • KRO $14.50
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 58.94
  • KRO 29.14
  • Support Level
  • ADPT $8.09
  • KRO $9.09
  • Resistance Level
  • ADPT $8.69
  • KRO $9.50
  • Average True Range (ATR)
  • ADPT 0.64
  • KRO 0.23
  • MACD
  • ADPT -0.00
  • KRO -0.06
  • Stochastic Oscillator
  • ADPT 65.66
  • KRO 5.98

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About KRO Kronos Worldwide Inc

Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in a variety of products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second-largest product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.

Share on Social Networks: